F-star signs deal with AbbVie for bispecific antibodies in immuno-oncology

11 January 2016
2019_biotech_test_vial_discovery_big

Biotech company F-star on Monday said it has entered into a collaboration and license agreement with US drugmaker AbbVie (NYSE: ABBV) to research and develop bispecific antibodies in immuno-oncology.

No financial terms were disclosed.

John Haurum, chief executive officer, said: “We are very excited to be working with AbbVie on these immuno-oncology programmes to develop new bispecific antibodies. Bispecific antibodies are expected to be the cornerstone of the next generation of immuno-oncology products and this collaboration validates our technology as truly novel and differentiated in the space.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology